Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - clonidine hydrochloride - solution for injection - 0.15 micromole(s) - imidazoline receptor agonists; clonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - clonidine hydrochloride - tablet - 0.1 milligram(s) - imidazoline receptor agonists; clonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - clonidine hydrochloride - solution for injection - 150 microgram(s)/millilitre - imidazoline receptor agonists; clonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - clonidine hydrochloride - tablet - 100 microgram(s) - imidazoline receptor agonists; clonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

glenwood gmbh - clonidine hydrochloride - solution for injection - 150 microgram(s)/millilitre - imidazoline receptor agonists; clonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

glenwood gmbh - clonidine hydrochloride - tablet - 100 microgram(s) - imidazoline receptor agonists; clonidine

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - attention deficit disorder with hyperactivity: methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of methamphetamine hydrochloride tablets, hypersensitivity reactions such as angioedema and anaphylactic reactions have been re

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - rilmenidine - tablet - rilmenidine 1 mg - antihypertensives

Malta - English - Medicines Authority

abbott healthcare products limited - moxonidine 0.4 mg - film-coated tablet

Malta - English - Medicines Authority

abbott healthcare products limited - moxonidine 0.2 mg - film-coated tablet